Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGXXNASDAQ:MURANASDAQ:NBRVNASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsMURAMural Oncology$2.60-1.1%$2.22$0.95▼$4.74$44.90M3.911.30 million shs17,269 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs146 shsXLOXilio Therapeutics$0.67-1.5%$0.78$0.62▼$1.70$34.47M-0.271.42 million shs559,187 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green0.00%0.00%0.00%+81.41%-78.72%MURAMural Oncology0.00%0.00%-0.38%-24.64%-22.87%NBRVNabriva Therapeutics0.00%0.00%0.00%+4,900.00%+4,900.00%XLOXilio Therapeutics-3.46%-23.19%-9.90%-25.68%-35.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology3.3305 of 5 stars3.35.00.00.02.51.71.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AXLOXilio Therapeutics2.4421 of 5 stars3.52.00.00.02.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright Green 0.00N/AN/AN/AMURAMural Oncology 2.60Moderate Buy$13.00400.00% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/AXLOXilio Therapeutics 3.00Buy$4.00500.96% UpsideCurrent Analyst Ratings BreakdownLatest BGXX, XLO, NBRV, and MURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00XLOXilio Therapeutics$9.27M3.72N/AN/A$1.34 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/AMURAMural Oncology-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/AXLOXilio Therapeutics-$76.40M-$0.84N/AN/AN/AN/A-211.50%-80.31%8/14/2025 (Estimated)Latest BGXX, XLO, NBRV, and MURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/13/2025Q1 2025XLOXilio Therapeutics$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 million3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/A3/11/2025Q4 2024XLOXilio Therapeutics-$0.22-$0.20+$0.02-$0.20$2.26 million$1.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.010.01MURAMural OncologyN/A7.387.38NBRVNabriva Therapeutics0.120.850.52XLOXilio TherapeuticsN/A1.671.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%MURAMural Oncology80.21%NBRVNabriva Therapeutics0.27%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipBGXXBright Green62.55%MURAMural Oncology0.06%NBRVNabriva Therapeutics1.63%XLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green2191.17 million71.59 millionNo DataMURAMural Oncology11917.27 million17.01 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableXLOXilio Therapeutics7051.78 million41.67 millionNot OptionableBGXX, XLO, NBRV, and MURA HeadlinesRecent News About These CompaniesXilio Therapeutics (NASDAQ:XLO) and Sophiris Bio (OTCMKTS:SPHS) Financial ComparisonJune 4 at 2:07 AM | americanbankingnews.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3 at 4:30 PM | globenewswire.comXilio Therapeutics Announces Pricing of $50.0 Million Public OfferingJune 2 at 8:46 AM | globenewswire.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...June 2 at 7:33 AM | stockhouse.comXilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C WarrantsJune 2 at 6:33 AM | quiverquant.comXilio Therapeutics Announces Proposed Public OfferingJune 2 at 6:11 AM | globenewswire.comXilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug TrialMay 31, 2025 | insidermonkey.comXilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal CancerMay 31, 2025 | quiverquant.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerMay 31, 2025 | globenewswire.comXilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short InterestMay 30, 2025 | americanbankingnews.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comXilio Therapeutics reports Q4 EPS (20c) vs (64c) last yearMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics files $250M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGXX, XLO, NBRV, and MURA Company DescriptionsBright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Mural Oncology NASDAQ:MURA$2.60 -0.03 (-1.14%) As of 01:13 PM EasternMural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Xilio Therapeutics NASDAQ:XLO$0.67 -0.01 (-1.52%) As of 01:24 PM EasternXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
